{"protocolSection":{"identificationModule":{"nctId":"NCT01586975","orgStudyIdInfo":{"id":"Aspirin Resistance and Stroke"},"secondaryIdInfos":[{"id":"IRB#0996-007 FUND#7810","type":"OTHER","domain":"Northwestern Memorial Hospital"}],"organization":{"fullName":"Northwestern University","class":"OTHER"},"briefTitle":"Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events","officialTitle":"Multiphase Study to Determine if Platelet Function Analysis Results Correlate With Ischemic Events and Bleeding Complications"},"statusModule":{"statusVerifiedDate":"2015-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2007-07"},"primaryCompletionDateStruct":{"date":"2010-04","type":"ACTUAL"},"completionDateStruct":{"date":"2011-12","type":"ACTUAL"},"studyFirstSubmitDate":"2011-08-03","studyFirstSubmitQcDate":"2012-04-26","studyFirstPostDateStruct":{"date":"2012-04-27","type":"ESTIMATED"},"resultsFirstSubmitDate":"2015-06-29","resultsFirstSubmitQcDate":"2015-10-27","resultsFirstPostDateStruct":{"date":"2015-12-03","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-12-02","lastUpdatePostDateStruct":{"date":"2015-12-31","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Northwestern University","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this study is to determine if PFA results correlate with ischemic event outcomes as well as bleeding complications. Hypothesis is antiplatelet agents will be more efficacious if they are administered in a dose-adjusted manner using PFA results as a guide.","detailedDescription":"Atherothrombotic disease is a leading killer of adults throughout the world. The current mainstay for the prevention of ischemic vascular events is the use of aspirin Antiplatelet agents are used routinely for the primary and secondary prevention of vascular events in patients with a prior history of stroke, TIA, or at high risk for the development of cerebrovascular disease. Numberous individual studies and meta-analyses have shown that essentially all of the oral antiplatelet agents have limited efficacy, with relative risk reductions in the range of 20-35%. The purpose of this study is to perform serial platelet function assays (PFAs) on patients with cerebrovascular disease who are taking antiplatelet agents and perform a pilot study to determine the feasibility of administering ASA as a dose adjusted medication using PFA. The long term goal of this study is to determine whether antiplatelet therapy will be more efficacious and/or safer if it is administered in a dose-adjusted manner."},"conditionsModule":{"conditions":["Stroke","Myocardial Infarctions"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2","PHASE3"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":93,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Clopidogrel 75 mg","type":"ACTIVE_COMPARATOR","description":"Clopidogrel 75 mg daily","interventionNames":["Drug: Clopidogrel"]},{"label":"Aspirin 81 mg","type":"ACTIVE_COMPARATOR","description":"open-label Aspirin 81 mg daily","interventionNames":["Drug: Aspirin 81 mg"]},{"label":"Aspirin > 300mg","type":"ACTIVE_COMPARATOR","description":"open-label Aspirin over 300 mg daily","interventionNames":["Drug: Aspirin >300 mg"]}],"interventions":[{"type":"DRUG","name":"Clopidogrel","description":"Clopidogrel 75 mg QD","armGroupLabels":["Clopidogrel 75 mg"],"otherNames":["Plavix"]},{"type":"DRUG","name":"Aspirin 81 mg","description":"Aspirin 81mg QD","armGroupLabels":["Aspirin 81 mg"],"otherNames":["Acetylsalicylic Acid","ASA"]},{"type":"DRUG","name":"Aspirin >300 mg","description":"Aspirin \\>300 mg QD","armGroupLabels":["Aspirin > 300mg"],"otherNames":["Acetylsalicylic Acid","ASA"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"PFA1","description":"Platelet Function Analysis (PFA) lab results: PFA was performed using the PFA 100 device (Dade-Behring), which uses a higher sheer stress flow cytometry paradigm to measure the time in seconds to closing of an aperture. Normal is defined as \\<172 seconds.\"","timeFrame":"3-6 months (Collected once between regulalary scheduled follow-up visit between 3-6 months)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient must be taking Aspirin or Plavix\n* Patient must have had a stroke, TIA or cerebrovascular disease\n\nExclusion Criteria:\n\n-None","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Mark J Alberts, MD","affiliation":"Northwestern University","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Northwestern University","city":"Chicago","state":"Illinois","zip":"60611","country":"United States","geoPoint":{"lat":41.85003,"lon":-87.65005}}]},"referencesModule":{"references":[{"pmid":"8784113","type":"BACKGROUND","citation":"Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF. Lifetime cost of stroke in the United States. Stroke. 1996 Sep;27(9):1459-66. doi: 10.1161/01.str.27.9.1459."}]}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"Patients with cerebrovascular disease and taking one or more antiplatelet medication were consented for study participation from 2007 though 2010. Patients were recruiting on the inpatient stroke unit at Northwestern Memorial Hospital and seen in the outpatient stroke clinic.","groups":[{"id":"FG000","title":"Clopidogrel 75 mg","description":"Clopidogrel 75 mg QD"},{"id":"FG001","title":"Aspirin 81 mg","description":"Aspirin 81 mg QD"},{"id":"FG002","title":"Aspirin > 300 mg","description":"Aspiring \\> 300 mg QD"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"32"},{"groupId":"FG002","numSubjects":"46"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"32"},{"groupId":"FG002","numSubjects":"46"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Clopidogrel 75 mg","description":"Clopidogrel 75 mg QD"},{"id":"BG001","title":"Aspirin 81 mg","description":"Aspirin 81 mg QD"},{"id":"BG002","title":"Aspiring >300 mg","description":"Aspirin \\>300 mg QD"},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"46"},{"groupId":"BG003","value":"93"}]}],"measures":[{"title":"Age, Customized","paramType":"MEAN","dispersionType":"FULL_RANGE","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"60.6","lowerLimit":"37","upperLimit":"83"},{"groupId":"BG001","value":"67.4","lowerLimit":"36","upperLimit":"93"},{"groupId":"BG002","value":"56.2","lowerLimit":"21","upperLimit":"87"},{"groupId":"BG003","value":"60.7","lowerLimit":"21","upperLimit":"93"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"26"},{"groupId":"BG003","value":"51"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"20"},{"groupId":"BG003","value":"42"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"4"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"13"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"37"},{"groupId":"BG003","value":"75"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"United States","categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"46"},{"groupId":"BG003","value":"93"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"PFA1","description":"Platelet Function Analysis (PFA) lab results: PFA was performed using the PFA 100 device (Dade-Behring), which uses a higher sheer stress flow cytometry paradigm to measure the time in seconds to closing of an aperture. Normal is defined as \\<172 seconds.\"","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Error","unitOfMeasure":"seconds","timeFrame":"3-6 months (Collected once between regulalary scheduled follow-up visit between 3-6 months)","groups":[{"id":"OG000","title":"Clopidogrel 75 mg","description":"Clopidogrel 75 mg QD"},{"id":"OG001","title":"Aspirin 81 mg","description":"open label Aspirin"},{"id":"OG002","title":"Aspirin > 300 mg","description":"open-label Aspirin"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"46"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"202.0","spread":"27.1"},{"groupId":"OG001","value":"271.1","spread":"14.9"},{"groupId":"OG002","value":"234.7","spread":"13.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001","OG002"],"groupDescription":"Kruskal-Wallis non-parametric ANOVA test","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0742","pValueComment":"p-value is not adjusted, and no a priori threshold was used","statisticalMethod":"Kruskal-Wallis","ciNumSides":"TWO_SIDED"}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Patients were monitored via routine clinic/office visits to determine if they had an ischemic vascular event or hemorrhagic event. These follow-up visits were scheduled every 3-6 months as per their regularly scheduled clinic follow-up visits.","eventGroups":[{"id":"EG000","title":"Clopidogrel 75 mg","description":"Clopidogrel 75 mg QD","seriousNumAffected":0,"seriousNumAtRisk":15,"otherNumAffected":2,"otherNumAtRisk":15},{"id":"EG001","title":"Aspirin 81 mg","description":"Aspirin 81 mg QD","seriousNumAffected":1,"seriousNumAtRisk":32,"otherNumAffected":3,"otherNumAtRisk":32},{"id":"EG002","title":"Aspirin >300 mg","description":"Aspirin \\>300 mg QD","seriousNumAffected":2,"seriousNumAtRisk":46,"otherNumAffected":2,"otherNumAtRisk":46}],"seriousEvents":[{"term":"Clinical Stroke","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"one patient suffered a clinical stroke","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46}]},{"term":"MI","organSystem":"Cardiac disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"one patient suffered a MI","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":46}]},{"term":"TIA","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"one patient suffered from a TIA","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":46}]}],"otherEvents":[{"term":"Nose bleeds","organSystem":"Vascular disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"4 patients suffered from nose bleeds","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":32},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":46}]},{"term":"Bruising","organSystem":"Immune system disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"minor bruising","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":32},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46}]},{"term":"GI bleeding","organSystem":"Gastrointestinal disorders","assessmentType":"SYSTEMATIC_ASSESSMENT","notes":"minor GI bleeding/blood in stool","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":32},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":46}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Northwestern University","organization":"Northwestern University","email":"r-bernstein@northwestern.edu","phone":"312.503.4394"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000009203","term":"Myocardial Infarction"},{"id":"D000007238","term":"Infarction"}],"ancestors":[{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000007511","term":"Ischemia"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000009336","term":"Necrosis"},{"id":"D000017202","term":"Myocardial Ischemia"},{"id":"D000006331","term":"Heart Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M9246","name":"Hemorrhage","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M11845","name":"Myocardial Infarction","asFound":"Myocardial Infarction","relevance":"HIGH"},{"id":"M9972","name":"Infarction","asFound":"Infarction","relevance":"HIGH"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"M6236","name":"Coronary Artery Disease","relevance":"LOW"},{"id":"M19196","name":"Myocardial Ischemia","relevance":"LOW"},{"id":"M9109","name":"Heart Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001241","term":"Aspirin"},{"id":"D000077144","term":"Clopidogrel"}],"ancestors":[{"id":"D000000894","term":"Anti-Inflammatory Agents, Non-Steroidal"},{"id":"D000018712","term":"Analgesics, Non-Narcotic"},{"id":"D000000700","term":"Analgesics"},{"id":"D000018689","term":"Sensory System Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000000893","term":"Anti-Inflammatory Agents"},{"id":"D000018501","term":"Antirheumatic Agents"},{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000010975","term":"Platelet Aggregation Inhibitors"},{"id":"D000016861","term":"Cyclooxygenase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000058633","term":"Antipyretics"},{"id":"D000058921","term":"Purinergic P2Y Receptor Antagonists"},{"id":"D000058919","term":"Purinergic P2 Receptor Antagonists"},{"id":"D000058914","term":"Purinergic Antagonists"},{"id":"D000058905","term":"Purinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"}],"browseLeaves":[{"id":"M4238","name":"Aspirin","asFound":"Knee","relevance":"HIGH"},{"id":"M1669","name":"Clopidogrel","asFound":"Results","relevance":"HIGH"},{"id":"M3907","name":"Anti-Inflammatory Agents","relevance":"LOW"},{"id":"M3908","name":"Anti-Inflammatory Agents, Non-Steroidal","relevance":"LOW"},{"id":"M3722","name":"Analgesics","relevance":"LOW"},{"id":"M20476","name":"Analgesics, Non-Narcotic","relevance":"LOW"},{"id":"M20294","name":"Antirheumatic Agents","relevance":"LOW"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"},{"id":"M13555","name":"Platelet Aggregation Inhibitors","relevance":"LOW"},{"id":"M18899","name":"Cyclooxygenase Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M28866","name":"Antipyretics","relevance":"LOW"},{"id":"M28984","name":"Purinergic P2Y Receptor Antagonists","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"Antipy","name":"Antipyretics"},{"abbrev":"Infl","name":"Anti-Inflammatory Agents"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"Analg","name":"Analgesics"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":true}